 |
市場調查報告書
商品編碼
1772631
美國的生物相似藥的公共衛生支出:資料主導的分析US Public Health Spending on Biosimilars: A Data Driven Analysis |
||||||
本報告全面分析了生物相似藥對美國公共衛生支出的影響，特別關注聯邦醫療保險（Medicare）和醫療補助（Medicaid）。報告深入探討了生物相似藥的審批、上市和應用動態，並深入分析了這些因素如何影響藥品支出。透過分析來自醫療保險和醫療補助服務中心 (CMS) 和美國食品藥物管理局 (FDA) 的數據，報告評估了生物相似藥與原廠生物製劑的成本效益，並重點分析了生物相似藥製造商的價格差異和收益表現。
此外，報告還探討了生物相似藥處方對患者獲得藥物和醫療保健成本的影響，並展望了隨著更多生物製劑專利到期而可能出現的市場變化。對於希望了解美國公共衛生體系中生物相似藥發展格局的製藥專業人士而言，本分析至關重要。
關鍵問題
- 1.生物相似藥如何影響聯邦醫療保險（Medicare）和醫療補助（Medicaid）的藥品支出？
- 2.美國公共醫療體系中生物相似藥的採用現況如何？
- 3.在聯邦醫療保險（Medicare）和醫療補助（Medicaid）中，生物相似藥的價格與原廠藥相比如何？
- 4.哪些生物相似藥製造商在公共報銷體系中創造了最多的收入？
- 5.生物相似藥對每張處方中生物製劑的支出削減效果如何？
- 6.生物相似藥的可近性如何影響聯邦醫療保險（Medicare）和醫療補助（Medicaid）的患者數量？
- 7.評估美國公共醫療體系中生物相似藥績效的關鍵指標是什麼？
- 8.聯邦醫療保險B部分和D部分中生物相似藥的報酬有何不同？
- 9.隨著許多生物製劑的專利到期，新的生物相似藥的預期影響是什麼？
- 10.本報告如何使用CMS數據來評估生物相似藥的採用與支出？
主要企業
|
|
調查手法
本報告基於獨立、簡潔的分析，該分析源自於專有的產業研究以及對產業意見領袖的深入訪談。這些報告深入分析了製藥企業高管需要了解的關鍵發展和市場趨勢，以應對未來的機會和課題。每份報告的重點都基於對二手文獻的回顧和已發現的知識差距。基於這些初步研究，我們制定了基於證據、專家意見的討論指南，以確保研究能夠解答最重要的問題。此外，我們制定了嚴格的篩選標準，以確保受訪者擁有足夠的經驗、知識和資格就該主題發表意見。
我們的報告有何獨特之處？
FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供詳細且可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助您掌握新興趨勢並有效應對複雜課題。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家獨家訪談和數據，以及持續的市場監測，讓您全面洞察市場動態。我們的報告涵蓋 40 多個活躍疾病領域，匯集醫生情報（包括 KOL 洞察和定量醫生調查），以及行業專家對醫療事務、數位醫療、銷售與市場營銷、市場准入及其他領域問題的看法，助您做出更明智的數據驅動決策，在快速變化的行業中保持競爭力。
This report provides a comprehensive analysis of the impact of biosimilars on US public health spending, specifically focusing on Medicare and Medicaid. It delves into the dynamics of biosimilar approvals, launches and uptake, offering insights into how these factors influence pharmaceutical expenditure. By examining data from the Centers for Medicare and Medicaid Services (CMS) and the FDA, the report evaluates the cost effectiveness of biosimilars compared to originator biologics, highlighting price differences and revenue achievements of biosimilar manufacturers.
Additionally, it explores the implications of biosimilar prescribing on patient access and healthcare costs, providing a forward-looking perspective on the potential market shifts as more biologic patents expire. This analysis is essential for pharmaceutical professionals seeking to understand the evolving landscape of biosimilars within the US public health system.
Key Questions Answered:
- 1. How have biosimilars impacted pharmaceutical expenditure under Medicare and Medicaid?
- 2. What is the current level of biosimilar uptake in the US public health system?
- 3. How do biosimilar and originator product prices compare within Medicare and Medicaid?
- 4. Which biosimilar manufacturers have achieved the greatest revenues in the public reimbursement system?
- 5. What is the effect of biosimilar prescribing on reducing expenditure for biologic products?
- 6. How has the availability of biosimilars influenced patient numbers under Medicare and Medicaid?
- 7. What are the key metrics used to assess biosimilar performance in the US public health system?
- 8. How do Medicare Part B and Part D differ in terms of biosimilar reimbursement?
- 9. What is the projected impact of newer biosimilars as more biologic patents expire?
- 10. How does the report utilise CMS data to evaluate biosimilar uptake and expenditure?
Key Companies:
|
|
Methodology:
Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
